Clene Inc., a clinical-stage nanotech pharmaceutical firm, receives multiple target price increases from investment firms.
Clene Inc., a clinical-stage pharmaceutical firm, has received a "strong-buy" upgrade from EF Hutton Acquisition Co. Additionally, HC Wainwright raised its price target from $7.00 to $31.00, while Canaccord Genuity set a target of $94.00, and Benchmark established a $100.00 target. Clene focuses on clean-surfaced nanotechnology therapeutics, with its lead candidate CNM-Au8 in clinical trials. The company's market cap is $39.40 million.
September 12, 2024
3 Articles